[Cisplatin, adriamycin and VP-16 (CAV) in the treatment of small cell carcinoma of the lung].
Sixteen patients with small cell carcinoma of the lung were treated with a combination of cisplatin (25 mg X 5 or 80 mg/m2 X 1), adriamycin (30 mg/m2 X 1) and VP-16 (200 mg (p.o) X 5) every 3-4 weeks. Nine of these patients had received prior therapy. In 12 evaluable patients, there were 9 partial responses and 1 complete response, giving a total response rate of 83.3% (10/12). 6 of 10 responders received radiation therapy after induction chemotherapy, and 4 patients achieved complete response. The median survival time of responders was 52 weeks. The major toxic effects included nausea and vomiting (81%), leukocytopenia less than 2,000 (75%), and thrombocytopenia less than 10 X 10(4) (44%). Renal toxicity was mild and none of these patients developed renal insufficiency. These results demonstrate that CAV is an effective regimen for remission induction chemotherapy in patients with small cell carcinoma of the lung.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000008:administration & dosage
D004317:Doxorubicin; D011034:Podophyllotoxin; D002945:Cisplatin